MACE, TVR and ST at 2 years follow-up
| Follow-up at 2 years | EES (%) | BMS (%) | p Value |
|---|---|---|---|
| Elisa-3 (n=173) | |||
| MACE | 10.7 | 14.6 | 0.442 |
| TVR | 4.8 | 11.2 | 0.119 |
| ST | 1.2 | 3.4 | 0.621 |
| Elisa Registry (n=282) | |||
| MACE | 13.6 | 16.9 | 0.437 |
| TVR | 3.6 | 9.9 | 0.035 |
| ST | 1.4 | 2.8 | 0.684 |
| Pooled Analysis (n=455) | |||
| MACE | 12.5 | 16.0 | 0.284 |
| TVR | 4.0 | 10.4 | 0.009 |
| ST | 1.3 | 3.0 | 0.339 |
BMS, bare-metal stent; EES, everolimus-eluting stent; MACE, major adverse cardiac events (composite of death, myocardial infarction and target vessel revascularisation); TVR, target vessel revascularisation; ST, stent thrombosis.